HPM Faculty News

Gellad on debate about CVS' use of ICER metrics

BIOPHARMA DIVE - More than 90 organizations, predominantly patient groups, criticized CVS Caremark's decision last month to incorporate value-based drug pricing analyses in some of its coverage choices, urging the company to reconsider in a Sept. 12 letter addressed to CVS CEO Larry Merlo. HPM's WALID GELLAD told BioPharma Dive that the actual action being debated may not be so severe.  

Gellad comments on benefits that could come from the Senate opioid response vote

POLITICO - The Senate is expected to pass a sweeping opioid crisis response package this week, paving the way for a final agreement between the two chambers. Even without direct savings, patients could benefit from lowered costs of hospital-administered drugs if the hospitals use that money to increase other services, says HPM’s Walid F. Gellad, head of Pitt's Center for Pharmaceutical Policy and Prescribing.  

Gellad comments on top cancer researcher who failed to disclose corporate financial ties in major research journals

NEW YORK TIMES - One of the world’s top breast cancer doctors failed to disclose millions of dollars in payments from drug and health care companies, omitting financial ties from research articles in prestigious publications like The New England Journal of Medicine and The Lancet. HPM’s Walid F. Gellad, head of Pitt's Center for Pharmaceutical Policy and Prescribing, said, “If leaders don’t follow the rules, then we don’t really have rules."  

Gellad on Scott Gottlieb's upending FDA communication

BIOPHARMA DRIVE - Scott Gotlieb, FDA commissioner, has been very vocal on twitter as a way to communicate the FDA's goals and to invite public comment and scrutiny. Stakeholders both inside and outside the agency have given Gottlieb credit for both transparency and effort. ButWalid Gellad, HPM faculty member and head of Pitt's Center for Pharmaceutical Policy and Prescribing, said there are risks to the volume and pace of Gottlieb's methods.  

Kahn speaks on the one percent solution that could help tame health care spending

NEW YORK TIMES - A group of economists is suggesting that many small tweaks, such as reigning in long-term care hospitals, could tame health care spending. HPM's JEREMY KAHN said there are some patients with particular ailments who benefit from the setting, but agreed with the economists that the hospitals are a historical accident, defined more by payment rules than patient needs.  

Roberts on new Trump administration policy that could hurt PA's health insurance marketplace

WESA-FM - A new health insurance rule from the Trump administration is being criticized by the Pennsylvania Insurance Department. The policy would jeopardize those who buy health insurance on the individual market. "If only sick people enter the individual market place, premiums become completely unaffordable," said HPM's ERIC ROBERTS.    

Gellad comments on potential conflicts of interests on Medicaid drug committees

NPR - The governor of Arizona removed a doctor from the state's Medicaid drug committee and issued an executive order requiring disclosure of financial conflicts in response to a joint investigation. HPM's Walid Gellad, director of Pitt's Center for Pharmaceutical Policy and Prescribing, says disclosing financial ties should be standard practice, especially for people serving on decision-making boards. "At least they can be out in the open."   

Gellad comments on Trump’s plan to bring down drug prices

STAT NEWS - Over the past week, the Trump administration has begun to clarify their proposals to lower drug prices. “They’re clearly still in early stages – a plan is still a plan, and a proposed rule can be a proposed rule for a long time, and a workgroup is just a workgroup,” said HPM’s Walid Gellad, who also serves as head of Pitt's Center for Pharmaceutical Policy and Prescribing. “But we’re ahead of where we were six months ago.”  

Gellad comments as Merck joins the list of drug makers agreeing to freeze or lower some prices

STAT NEWS - As political pressure on the pharmaceutical industry builds, Merck has become the latest big drug maker to commit to halting price hikes. In a brief statement, the company agreed not to increase the average net prices of its medicines by more than inflation annually. “We’re now seeing an effort to address pricing that we haven’t seen before,” said HPM's Walid Gellad, head of Pitt's Center for Pharmaceutical Policy and Prescribing.  

Gellad's take on drugmakers defiance to Trump's call to drop prices

POLITICO - President Donald Trump said that drugmakers would soon announce “massive” price cuts, and his administration rolled out a plan to bring down medicine costs. But companies don’t appear to have gotten the message. “The bully pulpit can't make fundamental change. It can provide perhaps a short-term victory...but it can’t do what the administration said,” said HPM's Walid Gellad, Center for Pharmaceutical Policy and Prescribing.   

HPM faculty researcher wins the 2018 AcademyHealth Article-of-the Year Award

A recent study, led by HPM’s ERIC ROBERTS has been named the 2018 Article-of-the-YearAcademyHealth, a leading national research center focused on advancing the fields of health services research and health policy. Entitled "The Value-Based Payment Modifier: Program Outcomes and Implications for Disparities," the work studied a precursor to the merit-based incentive payment system, Medicare’s new pay-for-performance program for physicians.  

Tribal Legal Preparedness Project now available on CDC Web site

The Tribal Legal Preparedness Project, created by HPM's TINA BATRA HERSHEY and the Center for Public Health Practice, is now available! Check it out and share with anyone who may be interested in emergency preparedness for Tribal Nations.   

Pittsburgh finds overdose risk quintuples with opioid and Benzodiazepine use

ASPPH FRIDAY LETTER - In the first 90 days of concurrent opioid and benzodiazepine use, the risk of opioid-related overdose increases five-fold compared to opioid-only use among Medicare recipients. "Having multiple prescribers who are not in communication increases the risk for overdose,” says HPM's YUTING ZHANG. "Policy interventions should focus on preventing concurrent exposure,” says INMACULADA HERNANDEZ (HPM '16).  

Pitt Public Health study helps inform new legislation sponsored by Sen Toomey (video)

In Sen Toomey's weekly e-newsletter, he announces that the Senate Finance Committee adopted his amendment, the Encouraging Appropriate Prescribing for Victims of Overdose in Medicare Act, to require Medicare to notify a doctor if their patient has suffered a non-fatal opioid overdose. Toomey references a study by experts including JULIE DONOHUE, HPM professor, in his discussion about the need to inform doctors of patient overdoses.   

Page 10 of 18First   Previous   5  6  7  8  9  [10]  11  12  13  14  Next   Last   

Search for an Article

Share News

Simply click to share news of your achievements—and those of classmates or colleagues. We’re eager to hear about and share stories of student, faculty, and alumni accomplishments. Email questions to phcomm@pitt.edu
or visit publichealth.pitt.edu/sharenews.

Share news